285,000 Shares in Pharvaris (NASDAQ:PHVS) Bought by Vivo Capital LLC

Vivo Capital LLC purchased a new position in shares of Pharvaris (NASDAQ:PHVS) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 285,000 shares of the company’s stock, valued at approximately $7,994,000.

Separately, Walleye Capital LLC boosted its position in Pharvaris by 15.2% during the 3rd quarter. Walleye Capital LLC now owns 81,017 shares of the company’s stock worth $1,691,000 after acquiring an additional 10,691 shares during the period.

Pharvaris Stock Down 2.5 %

NASDAQ:PHVS traded down $0.52 during trading hours on Thursday, hitting $20.33. 3,812 shares of the company’s stock traded hands, compared to its average volume of 97,322. Pharvaris has a twelve month low of $7.93 and a twelve month high of $33.00. The stock’s fifty day moving average price is $22.97 and its two-hundred day moving average price is $23.59.

Pharvaris (NASDAQ:PHVS) last released its quarterly earnings results on Wednesday, April 10th. The company reported ($0.80) earnings per share (EPS) for the quarter. On average, sell-side analysts forecast that Pharvaris will post -2.2 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on PHVS shares. JMP Securities boosted their price target on Pharvaris from $49.00 to $50.00 and gave the stock a “market outperform” rating in a research report on Thursday, April 11th. Morgan Stanley restated an “overweight” rating and issued a $34.00 price objective on shares of Pharvaris in a report on Monday, April 22nd. Finally, Wedbush cut their price objective on Pharvaris from $35.00 to $31.00 and set an “outperform” rating for the company in a report on Thursday.

Pharvaris Company Profile

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE).